VYNE - VYNE Therapeutics shares gain 5% on advancement of FMX114 in atopic dermatitis

VYNE Therapeutics (VYNE) perks 5% premarket after announcing its development plans for FMX114 for the potential treatment of mild-to-moderate atopic dermatitis ((AD)).Phase 2a clinical trial evaluating FMX114 is expected to begin in Q3 with top-line results anticipated by year end. FMX114 was evaluated in a nonclinical mice model with 100µl topical dinitrochlorobenzene ((DNCB)) solution to induce a type 2 inflammatory response in the skin with AD-like pathology.Treatment with FMX114 0.6% tofacitinib + 0.01% fingolimod combination gel resulted in an 89% reduction in the modified atopic dermatitis index score (mADI) relative to the DNCB control group at day 7.Both FMX114 doses had comparable efficacy to triamcinolone 0.1% cream.FMX114-treated animals experienced body weight gains comparable to DNCB groups at day 7.The company will host a conference call on March 4, at 8:30 am ET to discuss its financial results for FY20 and provide a business update.

For further details see:

VYNE Therapeutics shares gain 5% on advancement of FMX114 in atopic dermatitis